Products are for research use only, not for human use

Heterogeneous preparation · identity partially verified

Cerebrolysin

Cerebrolysin is a hydrolysate of porcine brain protein: free amino acids and hundreds of short peptides, with no single sequence, formula or structure. Its exact composition differs between analyses, and it is authorised as a medicine in some countries and in none of the three this library checks.

Updated · 33 sources read · How this library is built

Cerebrolysin in brief

Cerebrolysin is not a single molecule but an enzymatic hydrolysate of porcine brain protein, developed in Austria and registered as a structurally diverse substance (CAS 12656-61-0). It has been described as about three quarters free amino acids and one quarter short peptides by nitrogen content, and one independent mass-spectrometry study identified 638 peptides, mostly tubulin, actin and myelin basic protein fragments, with no neurotrophic factor fragments found; a second study of a different fraction reported 14,635 sequences, so the composition read out depends on the sample and the method. It is a licensed medicine in some countries, widely used in Russia, eastern Europe, China and other Asian and post-Soviet countries according to a 2023 Cochrane review, and it holds no authorisation from the FDA, Health Canada or the European Medicines Agency's central procedure. Most cell and animal evidence comes from neuronal cultures and rodent models, much of it from the manufacturer or its collaborators, and no component carrying the measured activity has been identified. Several animal studies from one laboratory were retracted in 2025 and 2026, and the Cochrane stroke review reports moderate-certainty evidence of an increase in non-fatal serious adverse events.[1,2,3,4,5,6,7,8]

Cerebrolysin regulatory status

This preparation is a licensed medicine in some jurisdictions and an unapproved substance in others, which is the first thing to establish about it. It holds no FDA or Health Canada marketing authorisation and no centrally authorised EU marketing authorisation: Drugs@FDA, the European Medicines Agency medicines database and the Health Canada Drug Product Database were each searched in November 2026 and return no record of it. Where it is authorised is stated in the literature rather than listed here country by country: a 2023 Cochrane review records that it is widely used in the treatment of acute ischaemic stroke in Russia, eastern Europe, China and other Asian and post-Soviet countries, and a 2024 comparative study describes it, along with eleven other brain-derived peptide preparations, as approved in some countries for neurological diseases without naming them. The clinical record that supports those authorisations is summarised by two Cochrane reviews, both of which graded their evidence low or very low on most outcomes; one of them reports moderate-certainty evidence of an increase in non-fatal serious adverse events, which is set out with its figures in the unresolved section below. It is not named on the World Anti-Doping Agency 2026 Prohibited List and does not appear on the FDA's list of bulk drug substances that may present significant safety risks (content current as of 22 April 2026). Four cited animal studies carry retractions, which the unresolved section names.[9,10,11,12,6,13,14,15]

Cerebrolysin at a glance

  • Cerebrolysin is an enzymatic digest of porcine brain protein, registered as a structurally diverse substance (CAS 12656-61-0, UNII 37KZM6S21G), not a single molecule.[1,3]
  • Its composition has been described as about three quarters free amino acids and one quarter peptides below about 10 kDa by nitrogen content; independent LC-MS profiling of one sample identified 638 peptides, mainly fragments of tubulin, actin and myelin basic protein.[2,3]
  • That same profiling found no fragments of GDNF, NGF, BDNF or CNTF, so the frequent label 'neurotrophic factor mixture' describes reported activity in assays, not identified ingredients.[3]
  • Most of the cell-level evidence comes from neuronal culture models (chick cortical neurons, PC12 cells, rat neural progenitor cells), and a large share of the literature was produced by, or funded by, the manufacturer.[2,16,17,18,19,5]
  • Several animal studies from one high-output laboratory have been retracted since 2025, which limits how much of the older mechanistic literature can be relied on.[7,20,8,21]

What is Cerebrolysin?

Cerebrolysin is a peptide preparation made by standardised enzymatic breakdown of pig brain proteins, developed in Austria (it appears in early papers under the code FPF-1070 and from the company then called EBEWE, later EVER Neuro Pharma). Regulatory registries treat it as a material defined by its source and process: the FDA substance record lists it as a protein fraction of Sus scrofa brain rather than as a chemical structure.[1,22,23,18]

The preparation has two broad parts. Free amino acids make up most of the nitrogen content, and a smaller peptide fraction is the part that cell studies attribute activity to. Several culture experiments separated the two by testing an artificial amino-acid mixture matching the free amino-acid component as a control; effects that persisted beyond that control were attributed to the peptides.[2,23,5]

The name is often confused with other brain-derived hydrolysates marketed in some countries (for example cerebroprotein hydrolysate, Cortexin and Cerebrolysat). Those are distinct products. Eleven such preparations, most based on cerebroprotein hydrolysate, gave reversed-phase HPLC peptide fingerprints that differed from Cerebrolysin and did not induce the neurofilament-L reporter in PC12 cells above an amino-acid control; cerebroprotein hydrolysate also differed in an endothelial permeability assay, and Cortexin, Cerebrolysat and Cognistar were compared with Cerebrolysin in a rat embolic stroke model. The fingerprint and reporter comparison was published by authors including a manufacturer employee, and the other two came from a laboratory that has repeatedly published with manufacturer co-authors.[12,24,25,19,26]

Not to be confused with

Cerebroprotein hydrolysate and other brain-derived peptide preparations (Cortexin, Cerebrolysat, Cognistar and others)
Separate products made from brain tissue by other processes. In one comparison, eleven cerebroprotein-hydrolysate-based and other brain peptide products gave reversed-phase HPLC fingerprints that differed from Cerebrolysin and did not induce the neurofilament-L reporter above an amino-acid control; cerebroprotein hydrolysate also did not reproduce Cerebrolysin's readout in an endothelial permeability assay, and Cortexin, Cerebrolysat and Cognistar were compared with it in a rat embolic stroke model. They are not interchangeable names for one material.[12,24,25]
Recombinant neurotrophic factors (NGF, BDNF, GDNF, CNTF)
Cerebrolysin is often described as 'neurotrophic', but an independent mass-spectrometry study found no fragments of these factors in the sample it analysed; the preparation is not a formulation of any of them.[3]
E021
A peptide fraction prepared from Cerebrolysin and tested separately in early rat studies; it is a sub-fraction, not the whole preparation.[34]
Semax
A single synthetic heptapeptide (an ACTH(4-10) analogue). It is a defined molecule; Cerebrolysin is a tissue hydrolysate. The two were compared side by side in one PC12 study.[35]

Cerebrolysin molecular structure

There is no single molecular structure to show. The best available description is peptidomic. Gevaert and colleagues (Ghent University, with an instrument vendor) analysed a sample bought over the internet by HPLC-ion trap and UHPLC-ion mobility-QTOF mass spectrometry, searched against the pig proteome and de novo sequenced, and identified 638 unique peptides. The most abundant came from alpha- and beta-tubulin, actin and myelin basic protein, which is what one would expect from digesting bulk brain protein.[3]

A Russian proteomics study of a 'light' peptide fraction reported far more sequences (14,635, mapped to 1,643 porcine proteins) and stated that the set included fragments matching enkephalins, orexin, neuropeptide VF, galanin and nerve growth factor. That count reflects a different instrument, depth and fraction, and the functional annotations in that paper are computational predictions rather than measured activities. The two studies therefore agree that the material is a very complex peptide mixture, and disagree on whether recognisable fragments of neurotrophic factors are present.[4,27,3]

Because composition is read at the level of a fingerprint, the manufacturer-affiliated literature characterises batches by chromatographic profile and by a cell-based potency assay (an EGFP reporter knocked into the neurofilament-L gene of PC12 cells) rather than by a list of active molecules.[5,12]

What studies on Cerebrolysin show

Each card names the experimental system and what was measured. A result in one system is not evidence about another.

The studies below did use this preparation, and the difficulty is the opposite of a blend's: the preparation has no fixed composition, so a result obtained on one batch is not automatically a result about another. One of the cards below is a 50-batch comparison in a reporter assay, and another fingerprints eleven different brain-derived products side by side, which is the measurement that makes batch identity a live question rather than a theoretical one.[5,12]

LC-MS peptidomics · Analytical chemistry, one commercially obtained sample

638 unique peptides identified, mainly from tubulin, actin and myelin basic protein; no fragments of GDNF, NGF, BDNF or CNTF were found.[3]

Material
Cerebrolysin (internet-obtained sample)
Measured
Peptide identities by HPLC-ion trap MS and UHPLC-ion mobility-QTOF MS with pig proteome search and de novo sequencing
Limitation
One sample of uncertain provenance; database-driven identification misses peptides that do not match the reference proteome. Read as abstract only.

Gevaert B et al., 2015, Drug Testing and Analysis

Primary neuronal culture · Embryonic chick cortical neurons under low-serum stress

After 8 days, Cerebrolysin but not the amino-acid mixture maintained MTT signal, and Cerebrolysin reduced the fraction of apoptotic nuclei; the amino-acid mixture matched it only at 4 days.[2]

Material
Cerebrolysin
Measured
MTT reduction at 4 and 8 days in vitro; percentage of nuclei with apoptotic chromatin
Compared with
Artificial amino-acid mixture matching the free amino-acid fraction; BDNF; FGF-2; fetal calf serum
Limitation
MTT measures mitochondrial dehydrogenase activity, not cell number; no specific peptide responsible was identified. Manufacturer-affiliated authors.

Hartbauer M et al., 2001, Journal of Neural Transmission

Explant culture, neurite outgrowth · Chicken embryo dorsal root, sympathetic and ciliary ganglion explants

Neurite outgrowth increased in dorsal root and sympathetic explants with an inverted-U concentration relationship, smaller than with NGF; no effect on ciliary ganglion neurons, which did respond to CNTF.[22]

Material
FPF-1070 (Cerebrolysin)
Measured
Neurite outgrowth from explants
Compared with
Phosphate-buffered saline; NGF and CNTF as positive controls
Limitation
Explant morphology only; did not identify a receptor or the active components.

Satou T et al., 2000, Journal of Neural Transmission

Cell reporter assay (methods) · PC12 cells with EGFP knocked in at the neurofilament-L locus (PC12-B)

Cerebrolysin batches and NGF increased reporter expression; the amino-acid component and the unrelated peptide mixture did not.[5]

Material
Cerebrolysin, 50 batches
Measured
EGFP-NF-L reporter fluorescence by flow cytometry after 4 days
Compared with
Free amino-acid component of Cerebrolysin; an unrelated peptide mixture (Prionex); NGF
Limitation
A differentiation marker in a rat tumour cell line; developed and validated with manufacturer-supplied material as a potency assay, not a mechanism study.

Seidl LF et al., 2024, Heliyon

Cell culture, signalling · Rat PC12 cells exposed to cobalt chloride (chemical hypoxia model)

Cerebrolysin reduced caspase-3/7 activation and superoxide and increased inhibitory phosphorylation of GSK3-beta in CoCl2-stressed cells.[18]

Material
Cerebrolysin
Measured
Cell diameter, caspase-3/7 activity, metabolic activity, superoxide, GSK3-beta phosphorylation
Compared with
Untreated CoCl2-exposed cells
Limitation
A chemical hypoxia mimic in a tumour line; the upstream receptor was not identified. Several authors employed by the manufacturer.

Hartwig K et al., 2014, International Journal of Developmental Neuroscience

Rat in vivo plus progenitor culture · Adult rat subventricular-zone neural progenitor cells; rat embolic middle cerebral artery occlusion

Cerebrolysin increased progenitor proliferation and phosphorylated Akt in culture, and LY294002 abolished the proliferation increase. In the companion study it increased Shh, patched and smoothened expression alongside progenitor proliferation and differentiation, and cyclopamine blocked those effects in culture and in the animal.[19]

Material
Cerebrolysin
Measured
BrdU incorporation, Tuj1-positive cells, phosphorylated Akt; in vivo BrdU and doublecortin counts. A companion study from the same laboratory used the smoothened inhibitor cyclopamine and measured Shh, patched and smoothened expression on the same systems
Compared with
Vehicle; PI3K inhibitor LY294002
Limitation
Pharmacological inhibitors throughout, not genetic knockdown, so neither study rules out an off-target action of the inhibitor; co-authors from the manufacturer on both. Infarct volume was not reduced in the in vivo arm of the first. The companion study was read as abstract only and a correction to it was published in 2025 whose content was not assessed here.

Zhang C et al., 2010, Journal of Neuroscience Research

Comparative peptide fingerprinting with a cell reporter bioassay · Reversed-phase HPLC peptide profiles, and the EGFP-neurofilament-L reporter PC12 line

The eleven products gave fingerprints that differed from the Cerebrolysin reference, and none of them induced the reporter appreciably above the amino-acid control, while the reference did. The same paper reports the size of the literature behind each: a PubMed search returned 570 publications for Cerebrolysin and 17 for cerebroprotein hydrolysate and none for the other preparations, and the Cochrane Library listed 270 trials for Cerebrolysin and 9 for cerebroprotein hydrolysate and none for the others.[12]

Material
One batch each of eleven brain-derived peptide products marketed for neurological disorders (Aktoseril, Cebonin, Cerabin-C, Cerebrain, Cerebrin, Cerebromine, Cerebropept, cerebroprotein hydrolysate, Neurovera, Newrolizine and Solesejin), against a Cerebrolysin reference
Measured
HPLC peptide fingerprint of each product, and reporter induction above the amino-acid control
Compared with
The Cerebrolysin reference, and an amino-acid control matching its free amino-acid fraction
Limitation
One batch per product, so it establishes that these preparations are not interchangeable with this one rather than characterising any of them, and a negative result in one reporter line is not an absence of activity. The authors include an employee of the Cerebrolysin manufacturer and the reference product is their own, which is why only the comparative composition result is taken from it here and none of its efficacy framing. It also measures nothing about batch-to-batch variation within Cerebrolysin itself.

Seidl LF et al., 2024, Journal of Medicine and Life

Enzyme activity in tissue homogenates · Rat liver, rat brain and human brain homogenates

Cerebrolysin inhibited all three KAT activities in a concentration-dependent way, most strongly KAT I.[28]

Material
Cerebrolysin
Measured
Kynurenine aminotransferase I, II and III activity by a radio-enzymatic method
Compared with
Assay without Cerebrolysin
Limitation
Crude homogenates; with a mixture rich in free amino acids, competition with assay substrates was not excluded in the abstract, and no single inhibitory component was identified.

Baran H et al., 2009, European Neuropsychopharmacology

How Cerebrolysin's activity has been probed in cell systems

No receptor for Cerebrolysin has been identified, and none is expected for a mixture. Mechanistic work instead measures downstream signalling after adding the whole preparation to cells. In rat neural progenitor cells it increased phosphorylated Akt, and a PI3K inhibitor removed the proliferation increase; in a separate study the Sonic hedgehog pathway inhibitor cyclopamine blocked progenitor responses. In PC12 cells under chemical hypoxia it increased the inhibitory phosphorylation of GSK3-beta.[19,26,18]

A recurring design is to compare the full preparation with a matched free amino-acid solution. In chick cortical neurons, neurite networks and the apoptosis readout separated the two after 8 days, and in the neurofilament-L reporter assay the amino-acid component alone gave no signal. That design attributes activity to the peptide fraction as a whole but does not say which peptides are responsible.[2,23,5]

In rodents, measurements of the neurotrophin system have been modest: in aged rats Cerebrolysin lowered proNGF and altered neocortical TrkA and p75NTR levels without changing total NGF or BDNF. These are tissue-level correlations in a named species and do not show that any component binds a Trk receptor.[29]

An abstract illustration standing for the kind of process this entry describes. It depicts no molecule and carries no text.
An abstract illustration, chosen to suit the kind of process this page describes. It is decoration rather than evidence: nothing in it is specific to this compound, nothing in it was measured, and it depicts no molecule. Generated from this entry's topic list. Volta Peptides compound library. CC0 1.0

What is still unknown about Cerebrolysin

Identity is defined by source and process, not by molecules. The two published peptidomic studies differ by more than twentyfold in the number of peptides found and disagree on whether fragments of neurotrophic factors are present. Neither identified a component shown to carry the activity measured in cell assays, and batch-to-batch comparisons are published mainly as chromatographic fingerprints by the manufacturer's collaborators.[3,4,12]

Research integrity is a live concern for the older animal literature. At least four transgenic mouse studies from the laboratory of Eliezer Masliah (Rett syndrome, CNTF-peptide comparison and two tauopathy papers) were retracted in 2025-2026. Other papers from the same group, including the APP-maturation, proNGF/NGF and NT2N synaptic-protein studies and the frequently cited 2012 pharmacology review, have not been retracted as of this reading but rest on the same body of work; they are cited here with that caveat.[7,20,8,21,30,31,32,33]

Independence is limited. Much of the cell and animal work was run by the manufacturer, its contract research organisation, or groups it funded, and the comparisons with competing hydrolysates were run by the same network. Independent analytical work (the Ghent peptidomics study) is sparse.[2,18,25,12,3]

The clinical record is described here by its shape and its harms, not by its claimed effects. Two Cochrane reviews cover it. The 2023 review of acute ischaemic stroke included seven randomised trials and 1,773 participants, one of them a trial of the related bovine-brain preparation Cortexin contributing 272 participants; it records that the manufacturer supported three of the multicentre studies either wholly or by supplying material, randomisation codes, grants or statisticians, judged risk of bias unclear across all studies for selective outcome reporting, and graded its outcomes from very low to moderate certainty. The 2019 review of vascular dementia included six randomised trials and 597 participants with mild to moderate severity, all of them industry-supported where funding was described, and graded every outcome very low quality. Traumatic brain injury has also been trialled, in the CAPTAIN series named in the 2024 comparative study's bibliography. One documented harm signal belongs on this page with its figures. The 2023 Cochrane review reports moderate-certainty evidence of an increase in the number of people with non-fatal serious adverse events, risk ratio 2.39 with a 95 per cent confidence interval of 1.10 to 5.23 across 3 trials and 1,335 participants, and states that the increase was more prominent in a subgroup receiving a higher cumulative exposure, risk ratio 2.87 (1.24 to 6.69) across 2 trials and 1,189 participants. Total serious adverse events and fatal serious adverse events showed little to no difference, as did all-cause death (risk ratio 0.96, 0.65 to 1.41, 6 trials, 1,689 participants, moderate certainty). The vascular dementia review found no difference in adverse-event rates in the two trials whose data could be pooled, on very low-quality evidence.[6,13,12]

Key papers on Cerebrolysin

  1. Peptide profiling of Internet-obtained Cerebrolysin using high performance liquid chromatography - electrospray ionization ion trap and ultra high performance liquid chromatography - ion mobility - quadrupole time of flight mass spectrometry.

    Gevaert B, D'Hondt M, Bracke N, Yao H, Wynendaele E, Vissers JP, De Cecco M, Claereboudt J, De Spiegeleer B (2015), Drug Testing and Analysis · LC-MS peptidomics

    The only independent, published peptidomic analysis; establishes what the preparation is made of and what it does not contain.

  2. Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons.

    Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M (2001), Journal of Neural Transmission · Primary neuronal culture

    Clear early design separating the peptide fraction from the free amino acids in a neuronal culture.

  3. A Neurofilament-L reporter cell line for the quantification of early neuronal differentiation: A Bioassay for neurotrophic activities.

    Seidl LF, Winter S, Aigner L, Schartner J (2024), Heliyon · Methods / cell reporter assay

    Describes the reporter cell assay now used to measure batch activity, including its negative controls.

  4. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke.

    Zhang C, Chopp M, Cui Y, Wang L, Zhang R, Zhang L, Lu M, Szalad A, Doppler E, Hitzl M, Zhang ZG (2010), Journal of Neuroscience Research · Cell culture and rat in vivo

    Open-access study linking the preparation to PI3K/Akt signalling in neural progenitor cells.

  5. Comparing the biological activity and composition of Cerebrolysin with other peptide preparations.

    Seidl LF, Aigner L (2024), Journal of Medicine and Life · Comparative analytics and bioassay

    Shows that brain-derived hydrolysates sold under other names have different HPLC fingerprints; read with its affiliation in mind.

  6. Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.

    Rockenstein E, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Masliah E (2015), BMC Neuroscience · Retracted animal study

    An example of the retracted transgenic-mouse literature; check retraction status before relying on any paper from that laboratory.

References

  1. 1.U.S. Food and Drug Administration / NCATS. CEREBROLYSIN (UNII 37KZM6S21G), Global Substance Registration System record. GSRS. source · database record
  2. 2.Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. (2001). Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. Journal of Neural Transmission. 108:459-473. doi:10.1007/s007020170067 · abstract only
  3. 3.Gevaert B, D'Hondt M, Bracke N, Yao H, Wynendaele E, Vissers JP, De Cecco M, Claereboudt J, De Spiegeleer B. (2015). Peptide profiling of Internet-obtained Cerebrolysin using high performance liquid chromatography - electrospray ionization ion trap and ultra high performance liquid chromatography - ion mobility - quadrupole time of flight mass spectrometry. Drug Testing and Analysis. 7:835-842. doi:10.1002/dta.1817 · abstract only
  4. 4.Gromova OA, Torshin IY, Zgoda VG, Tikhonova OV. (2019). [An analysis of the peptide composition of a 'light' peptide fraction of cerebrolysin]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 119:75-83. doi:10.17116/jnevro201911908175 · abstract only
  5. 5.Seidl LF, Winter S, Aigner L, Schartner J. (2024). A Neurofilament-L reporter cell line for the quantification of early neuronal differentiation: A Bioassay for neurotrophic activities. Heliyon. 10:e24753. doi:10.1016/j.heliyon.2024.e24753 · full text read
  6. 6.Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. (2023). Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews. 10:CD007026. doi:10.1002/14651858.CD007026.pub7 · abstract only
  7. 7.Rockenstein E, Ubhi K, Doppler E, Novak P, Moessler H, Li B, Blanchard J, Grundke-Iqbal I, Iqbal K, Mante M, Adame A, Crews L, Masliah E. (2011). Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AβPP transgenic mice. Journal of Alzheimer's Disease. 27:743-752. doi:10.3233/JAD-2011-110914 · abstract only · retracted: Retracted: J Alzheimers Dis 2026;111(4):1893, doi 10.1177/13872877261442048 (per PubMed record).
  8. 8.Rockenstein E, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Masliah E. (2015). Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies. BMC Neuroscience. 16:85. doi:10.1186/s12868-015-0218-7 · abstract only · retracted: Retracted: BMC Neurosci 2025;26(1):23, doi 10.1186/s12868-025-00942-y (per PubMed record).
  9. 9.U.S. Food and Drug Administration. (2026). Drugs@FDA: FDA-Approved Drugs. U.S. Food and Drug Administration. source · database record
  10. 10.European Medicines Agency. (2026). Medicines. European Medicines Agency. source · database record
  11. 11.Health Canada. (2026). Drug Product Database online query. Health Canada. source · database record
  12. 12.Seidl LF, Aigner L. (2024). Comparing the biological activity and composition of Cerebrolysin with other peptide preparations. Journal of Medicine and Life. 17:24-27. doi:10.25122/jml-2024-0129 · full text read
  13. 13.Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. (2019). Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews. 2019:CD008900. doi:10.1002/14651858.CD008900.pub3 · abstract only
  14. 14.World Anti-Doping Agency. (2026). The 2026 Prohibited List: International Standard. World Anti-Doping Agency. source · full text read
  15. 15.U.S. Food and Drug Administration. (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. source · full text read
  16. 16.Gutmann B, Hutter-Paier B, Skofitsch G, Windisch M, Gmeinbauer R. (2002). In vitro models of brain ischemia: the peptidergic drug cerebrolysin protects cultured chick cortical neurons from cell death. Neurotoxicity Research. 4:59-65. doi:10.1080/10298420290007637 · abstract only
  17. 17.Schauer E, Wronski R, Patockova J, Moessler H, Doppler E, Hutter-Paier B, Windisch M. (2006). Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window. Journal of Neural Transmission. 113:855-868. doi:10.1007/s00702-005-0384-3 · abstract only
  18. 18.Hartwig K, Fackler V, Jaksch-Bogensperger H, Winter S, Furtner T, Couillard-Despres S, Meier D, Moessler H, Aigner L. (2014). Cerebrolysin protects PC12 cells from CoCl2-induced hypoxia employing GSK3β signaling. International Journal of Developmental Neuroscience. 38:52-58. doi:10.1016/j.ijdevneu.2014.07.005 · abstract only
  19. 19.Zhang C, Chopp M, Cui Y, Wang L, Zhang R, Zhang L, Lu M, Szalad A, Doppler E, Hitzl M, Zhang ZG. (2010). Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. Journal of Neuroscience Research. 88:3275-3281. doi:10.1002/jnr.22495 · full text read
  20. 20.Doppler E, Rockenstein E, Ubhi K, Inglis C, Mante M, Adame A, Crews L, Hitzl M, Moessler H, Masliah E. (2008). Neurotrophic effects of Cerebrolysin in the Mecp2(308/Y) transgenic model of Rett syndrome. Acta Neuropathologica. 116:425-437. doi:10.1007/s00401-008-0407-x · abstract only · retracted: Retracted: Acta Neuropathol 2026;151(1):30, doi 10.1007/s00401-026-03001-w (per PubMed record).
  21. 21.Rockenstein E, Ubhi K, Trejo M, Mante M, Patrick C, Adame A, Novak P, Jech M, Doppler E, Moessler H, Masliah E. (2014). Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure. BMC Neuroscience. 15:90. doi:10.1186/1471-2202-15-90 · abstract only · retracted: Retracted: BMC Neurosci 2025;26(1):67, doi 10.1186/s12868-025-00985-1 (per PubMed record).
  22. 22.Satou T, Itoh T, Tamai Y, Ohde H, Anderson AJ, Hashimoto S. (2000). Neurotrophic effects of FPF-1070 (Cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks. Journal of Neural Transmission. 107:1253-1262. doi:10.1007/s007020070015 · abstract only
  23. 23.Hartbauer M, Hutter-Paier B, Windisch M. (2001). Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons. Journal of Neural Transmission. 108:581-592. doi:10.1007/s007020170058 · abstract only
  24. 24.Teng H, Li C, Zhang Y, Lu M, Chopp M, Zhang ZG, Melcher-Mourgas M, Fleckenstein B. (2021). Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability. Neuroreport. 32:359-366. doi:10.1097/WNR.0000000000001598 · abstract only
  25. 25.Zhang L, Chopp M, Wang C, Zhang Y, Lu M, Zhang T, Zhang ZG. (2019). Prospective, double blinded, comparative assessment of the pharmacological activity of Cerebrolysin and distinct peptide preparations for the treatment of embolic stroke. Journal of the Neurological Sciences. 398:22-26. doi:10.1016/j.jns.2019.01.017 · abstract only
  26. 26.Zhang L, Chopp M, Meier DH, Winter S, Wang L, Szalad A, Lu M, Wei M, Cui Y, Zhang ZG. (2013). Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke. Stroke. 44:1965-1972. doi:10.1161/STROKEAHA.111.000831 · abstract only · corrected: A correction was published in Stroke 2025;56(2):e99 (doi 10.1161/STR.0000000000000484). Its content was not read for this entry.
  27. 27.Gromova OA, Torshin IY, Stakhovskaia LV, Maiorova LA, Ostrenko KS. (2019). [Comparative studies of neurotrophic drugs based on brain hydrolysates]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 119:134-140. doi:10.17116/jnevro2019119101134 · abstract only
  28. 28.Baran H, Kepplinger B. (2009). Cerebrolysin lowers kynurenic acid formation--an in vitro study. European Neuropsychopharmacology. 19:161-168. doi:10.1016/j.euroneuro.2008.09.003 · abstract only
  29. 29.Stepanichev M, Onufriev M, Aniol V, Freiman S, Brandstaetter H, Winter S, Lazareva N, Guekht A, Gulyaeva N. (2017). Effects of cerebrolysin on nerve growth factor system in the aging rat brain. Restorative Neurology and Neuroscience. 35:571-581. doi:10.3233/RNN-170724 · full text read
  30. 30.Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E. (2006). Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. Journal of Neuroscience Research. 83:1252-1261. doi:10.1002/jnr.20818 · abstract only
  31. 31.Ubhi K, Rockenstein E, Vazquez-Roque R, Mante M, Inglis C, Patrick C, Adame A, Fahnestock M, Doppler E, Novak P, Moessler H, Masliah E. (2013). Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease. Journal of Neuroscience Research. 91:167-177. doi:10.1002/jnr.23142 · abstract only
  32. 32.Mallory M, Honer W, Hsu L, Johnson R, Rockenstein E, Masliah E. (1999). In vitro synaptotrophic effects of Cerebrolysin in NT2N cells. Acta Neuropathologica. 97:437-446. doi:10.1007/s004010051012 · abstract only
  33. 33.Masliah E, Díez-Tejedor E. (2012). The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs of Today. 48 Suppl A:3-24. doi:10.1358/dot.2012.48(Suppl.A).1739716 · abstract only
  34. 34.Gschanes A, Boado R, Sametz W, Windisch M. (2000). The drug cerebrolysin and its peptide fraction E021 increase the abundance of the blood-brain barrier GLUT1 glucose transporter in brains of young and old rats. Histochemical Journal. 32:71-77. doi:10.1023/a:1004003008683 · abstract only
  35. 35.Safarova ER, Shram SI, Grivennikov IA, Myasoedov NF. (2002). Trophic effects of nootropic peptide preparations cerebrolysin and semax on cultured rat pheochromocytoma. Bulletin of Experimental Biology and Medicine. 133:401-403. doi:10.1023/a:1016270626439 · abstract only
  36. 36.National Center for Biotechnology Information. PubChem compound name lookup for Cerebrolysin (PUG REST). PubChem. source · database record
  37. 37.European Molecular Biology Laboratory, European Bioinformatics Institute. ChEBI ontology search for cerebrolysin (OLS4). ChEBI via EMBL-EBI Ontology Lookup Service. source · database record

Scope. This entry describes chemistry, structure and published laboratory findings. It is not guidance on use of any kind.

Sources read: 33 distinct works. Researched 2026-11-03. Detailed review 2026-11-02. How this library is built.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.